Daniel Olson

Background

About Daniel Olson

My research focuses on advancing immunotherapeutic approaches to the treatment of solid tumors, with a particular focus on adoptive cell therapy. I have dedicated clinical expertise in cutaneous oncology and sarcomas, though I treat all solid tumors through clinical research in early phase drug development. I helped to complete and report a practice-changing study of anti-PD-1 plus low-dose ipilimumab after prior anti-PD-1 failure in advanced melanoma. Within my institution, I am leading multiple immunotherapy clinical trials including tumor-infiltrating lymphocyte (TILs), TCR T cell, and CAR-T cell therapies. I co-lead one of the largest TIL centers for melanoma in the country. I also lead studies targeting immune checkpoints and agonists (DGKz, CCR8, cytokines), innate immune agonists (STING) as well as oncolytic virus therapies. I have also contributed to translational research relating to biomarkers of immunotherapy response and immune-related adverse events (irAEs) to immune checkpoint therapy.